MDS
MCID: MYL040
MIFTS: 79

Myelodysplastic Syndromes (MDS) malady

Genetic diseases, Rare diseases, Cancer diseases categories
Download this MalaCard

Summaries for Myelodysplastic Syndromes

About this section
Sources:
43NIH Rare Diseases, 34MedlinePlus, 65Wikipedia, 47OMIM, 33MalaCards
See all sources

Fully expand this MalaCard
MedlinePlus:34 Your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. it contains immature cells, called stem cells. the stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting. if you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. many of them die in the bone marrow. this means that you do not have enough healthy cells, which can lead to infection, anemia, or easy bleeding. myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. if you have symptoms, they may include shortness of breath weakness or feeling tired skin that is paler than usual easy bruising or bleeding pinpoint spots under the skin caused by bleeding fever or frequent infections myelodysplastic syndromes are rare. people at higher risk are over 60, have had chemotherapy or radiation therapy, or have been exposed to certain chemicals. treatment options include transfusions, drug therapy, chemotherapy, and blood or bone marrow stem cell transplants. nih national cancer institute

MalaCards: Myelodysplastic Syndromes, also known as dysmyelopoietic syndromes, is related to leukemia and myeloid leukemia. An important gene associated with Myelodysplastic Syndromes is GATA2 (GATA binding protein 2), and among its related pathways are G protein signaling K RAS regulation pathway and Paxillin-dependent events mediated by a4b1. The compounds erex and bmmp have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related mouse phenotypes are renal/urinary system and tumorigenesis.

NIH Rare Diseases:43 Myelodysplastic syndromes (mds) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. individuals with mds have abnormally low blood cell levels (low blood counts). signs and symptoms associated with mds include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. in some cases, mds may progress to bone marrow failure or an acute leukemia. the exact cause of mds is unknown. it sometimes runs in families, but no disease-causing gene has been identified. treatment depends on the affected individual's age, general health, and type of mds and may include red cell and/or platelet transfusions and antibiotics. last updated: 3/23/2012

Wikipedia:65 The myelodysplastic syndromes (also known as MDS or myelodysplasia) are hematological (blood-related)... more...

Description from OMIM:47 614286

Aliases & Classifications for Myelodysplastic Syndromes

About this section
Sources:
43NIH Rare Diseases, 22GTR, 45Novoseek, 34MedlinePlus, 31LifeMap Discovery™, 47OMIM, 62UMLS, 25ICD10
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Genetic diseases, Rare diseases, Cancer diseases


Aliases & Descriptions:

myelodysplastic syndromes 43 22 45 34 31
dysmyelopoietic syndromes 62
myelodysplastic syndrome 47
mds 43


External Ids:

ICD1025 D46, D46.6, D46.9

Related Diseases for Myelodysplastic Syndromes

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Myelodysplastic Syndromes via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 401)
idRelated DiseaseScoreTop Affiliating Genes
1leukemia31.7CDKN2B, ASXL1, IL3, DNTT, CSF2, CSF3
2myeloid leukemia31.6CSF3, CDKN2B, MNDA, MPL, IL3, DNTT
3refractory anemia31.2CSF3, CSF2, IL3, FTMT, EPO, EPOR
4chronic myelomonocytic leukemia31.2CSF3, MPL, CSF2
5aplastic anemia31.2GATA2, CSF3, CSF2, IL3, MPL, EPO
6acute leukemia30.9GATA2, CDKN2C, CDKN2B, CD33, CSF3, CSF2
7myeloproliferative disorder30.9CSF3, EPOR, MPL, CSF2, EPO, IL3
8juvenile myelomonocytic leukemia30.9CSF2, NRAS
9myelofibrosis30.9MPL, EPO
10pancytopenia30.8CSF2, CSF3, IL3, EPO, MPL
11pulmonary alveolar proteinosis30.8CSF2, IL3
12thrombocytopenia30.7EPO, IL3, CSF2, CSF3, MPL
13neutropenia30.7MPL, EPOR, EPO, IL3, CSF2, CSF3
14myeloma30.7ANG, IL3, DNTT, CSF2, CSF3, CDKN2C
15graft versus host disease30.6CSF3, IL3, CSF2
16thrombocytosis30.6MPL, EPOR, EPO, ASXL1, IL3, CSF2
175q- syndrome30.6EPO
18breast cancer30.5BOK, EPOR, GATA2, CSF2, NRAS, CDKN2C
19acute promyelocytic leukemia30.5DNTT, CSF3, IL3, NRAS, GATA2, CD33
20splenomegaly30.4MPL, EPO, CSF3
21hodgkin's lymphoma30.4CDKN2C, IL3, CSF2, CSF3
22polycythemia vera30.3IL3, ASXL1, MPL, EPOR, EPO
23lymphoblastic lymphoma30.2CDKN2B, DNTT
24lung cancer30.2CDKN2B, CSF3, CDKN2C, CSF2, DNTT
25ovarian cancer30.2ANG, NRAS, IL3, CSF2, CSF3, CDKN2C
26severe congenital neutropenia autosomal recessive 330.1CSF2, CSF3, IL3
27cyclic hematopoiesis30.1IL3, CSF2, CSF3
28leukemoid reaction30.1CSF3, CSF2, IL3
29severe congenital neutropenia30.1CSF2, CSF3, IL3
30polycythemia30.1MPL, EPOR, EPO, IL3
31chronic lymphocytic leukemia30.0CSF2, CDKN2B, DNTT
32acute erythroid leukemia30.0EPOR, DNTT, CSF2, EPO, IL3, MPL
33non-hodgkin lymphoma30.0CDKN2B, CSF3, CDKN2C, CSF2, IL3, DNTT
34diamond-blackfan anemia30.0IL3, EPO
35melanoma30.0EPOR, CSF2, MNDA, NRAS, CDKN2C, CDKN2B
36acute myeloid leukemia11.1
37hematopoietic stem cell transplantation10.6
38relapsing polychondritis10.5
39muscular dystrophy10.5
40hemoglobinuria10.5
41paroxysmal nocturnal hemoglobinuria10.5
42pyoderma10.5
43pyoderma gangrenosum10.4
44lymphoblastic leukemia10.4
45chromosome 5q deletion10.4
46thalassemia10.4
47refractory anemia with excess blasts10.4
48pure red-cell aplasia10.4
49alpha thalassemia10.4
50multiple myeloma10.4

Graphical network of the top 20 diseases related to Myelodysplastic Syndromes:



Diseases related to myelodysplastic syndromes

Symptoms for Myelodysplastic Syndromes

About this section
Sources:
47OMIM
See all sources


Clinical features from OMIM:

614286

Drugs & Therapeutics for Myelodysplastic Syndromes

About this section
Sources:
42NIH Clinical Center, 6ClinicalTrials, 31LifeMap Discovery™, 62UMLS, 41NDF-RT
See all sources

Genetic Tests for Myelodysplastic Syndromes

About this section
Sources:
22GTR
See all sources

Genetic tests related to Myelodysplastic Syndromes:

id Genetic test Affiliating Genes
1 Myelodysplastic Syndrome22

Anatomical Context for Myelodysplastic Syndromes

About this section
Sources:
31LifeMap Discovery™, 33MalaCards
See all sources

MalaCards organs/tissues related to Myelodysplastic Syndromes:

33
Myeloid, Bone, Bone marrow, Testes, Skin, T cells, Monocytes, Breast, Endothelial, Lung, B cells, Liver, Spleen, Nk cells, Thyroid, Colon, Heart, Ovary, Spinal cord, Brain, Prostate

LifeMap Discovery
The database of embryonic development, stem cell research and regenerative medicine

Cells/anatomical compartments in embryo or adult related to Myelodysplastic Syndromes:
id TissueAnatomical CompartmentCell Relevance
1 PlacentaChorionic VillusChorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 BloodCord BloodMesenchymal Stem Cells Potential therapeutic candidate
3 Umbilical CordWharton's JellyMesenchymal Stem Cells Potential therapeutic candidate

Animal Models for Myelodysplastic Syndromes or affiliated genes

About this section
Sources:
37MGI
See all sources

MGI Mouse Phenotypes related to Myelodysplastic Syndromes:

37 (show all 13)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053679.8IL3, CSF2, CSF3, GATA2, CDKN2C, CDKN2B
2MP:00020069.7IL3, CSF2, BOK, NRAS, CDKN2C, CDKN2B
3MP:00053809.7MPL, POGLUT1, EPOR, EPO, CSF2, NRAS
4MP:00028739.7GATA2, NRAS, DNTT, FTMT, EPO, EPOR
5MP:00053799.6POGLUT1, IL3, CSF2, GATA2, CDKN2C, CDKN2B
6MP:00053859.6POGLUT1, EPOR, EPO, CSF2, NRAS, GATA2
7MP:00053709.5POGLUT1, EPOR, EPO, NRAS, GATA2
8MP:00107719.5EPO, CSF2, CSF3, NRAS, CDKN2C, CDKN2B
9MP:00053849.4MPL, EPOR, EPO, ASXL1, IL3, CSF2
10MP:00053769.3IL3, EPO, EPOR, MPL, CSF2, NRAS
11MP:00107689.2EPO, EPOR, POGLUT1, MPL, ASXL1, IL3
12MP:00053878.9DNTT, IL3, ASXL1, EPOR, MPL, CSF2
13MP:00053978.7CD33, MPL, EPOR, EPO, ASXL1, IL3

Publications for Myelodysplastic Syndromes

About this section
Sources:
52PubMed
See all sources

Articles related to Myelodysplastic Syndromes:

(show top 50)    (show all 1826)
idTitleAuthorsYear
1
Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. (24434998)
2014
2
Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients. (24127668)
2013
3
NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. (23708912)
2013
4
Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. (23259989)
2013
5
Fatal Nocardia farcinica Bacteremia Diagnosed by Matrix-Assisted Laser Desorption-Ionization Time of Flight Mass Spectrometry in a Patient with Myelodysplastic Syndrome Treated with Corticosteroids. (23690786)
2013
6
Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome. (23826588)
2013
7
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine. (23740492)
2013
8
Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines. (24192507)
2013
9
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. (23153525)
2013
10
Large-vessel thrombosis in intestinal BehAset's disease complicated with myelodysplastic syndrome and trisomy 8. (22416191)
2012
11
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? (22177456)
2012
12
Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients. (22508616)
2012
13
Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. (21233837)
2011
14
Myelodysplastic syndromes. (22118747)
2011
15
Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes. (22200086)
2011
16
Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature. (20371446)
2010
17
Single nucleotide polymorphisms in the human TNF gene are associated with anaemia and neutropenia in a cohort of patients with de novo myelodysplastic syndrome. (20618340)
2010
18
Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes*. (20002157)
2010
19
Mutation analysis of the HAX1 gene in childhood myelodysplastic syndrome. (19298594)
2009
20
Update on genetic and molecular markers associated with myelodysplastic syndromes. (19263296)
2009
21
Expression of cyclin A1 mRNA in patients with myelodysplastic syndrome and its clinical significance]. (19379570)
2009
22
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. (17940203)
2008
23
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. (18195096)
2008
24
Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes. (18464119)
2008
25
Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. (18367246)
2008
26
GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes. (17570514)
2007
27
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. (17550846)
2007
28
A case of myelodysplastic syndrome complicated with organizing pneumonia]. (17233390)
2006
29
WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes. (16800930)
2006
30
Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density. (15888251)
2005
31
Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes. (15863212)
2005
32
The geldanamycin derivative 17-AAG decreases VEGF secretion and leukemia growth support by trisomy 8 myelodysplastic syndrome bone marrow stromal cells. (15804996)
2005
33
Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors. (15590394)
2004
34
Survivin expression in acute leukemias and myelodysplastic syndromes. (15512811)
2004
35
Cord blood transplantation supported with ex vivo expanded fraction for a patient with myelodysplastic syndrome and metastatic breast cancer]. (15510834)
2004
36
Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. (15147372)
2004
37
Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. (12681357)
2003
38
Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. (12937849)
2003
39
Secondary pulmonary alveolar proteinosis associated with myelodysplastic syndrome. (12636240)
2003
40
Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. (12469185)
2003
41
Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. (11830484)
2002
42
Cellular abundance of es nucleoside transporters and differential drug toxicity in myelodysplastic syndrome (MDS) bone marrow cell subpopulations. (11794010)
2001
43
An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide]. (10774251)
2000
44
Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. (10997969)
2000
45
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. (10211754)
1999
46
Molecular heterogeneity of the NUP98/HOXA9 fusion transcript in myelodysplastic syndromes associated with t(7;11)(p15;p15). (10583265)
1999
47
Hemoglobin F in myelodysplastic syndrome. (9619730)
1998
48
Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase. (7532031)
1994
49
Response of hematopoietic precursor cells to hematopoietic growth factors in the myelodysplastic syndromes. (2099409)
1990
50
Translocation t(6;9)(p22.3;q34) in myelodysplastic syndrome--refractory anemia with excess blasts. (3664444)
1987

Variations for Myelodysplastic Syndromes

About this section
Sources:
64UniProtKB/Swiss-Prot, 1 National Center for Biotechnology Information (Clinvar)
See all sources

UniProtKB/Swiss-Prot genetic disease variations for Myelodysplastic Syndromes:

64
id Symbol AA change Variation ID SNP ID
1GATA2p.Thr354MetVAR_066406
2SETBP1p.Asp868AsnVAR_063807
3SETBP1p.Gly870SerVAR_063809
4SETBP1p.Ser869AsnVAR_069852
5SETBP1p.Thr873ArgVAR_069857

Clinvar genetic disease variations for Myelodysplastic Syndromes:

1
id Gene Name Type Significance SNP ID Assembly Location
1GATA2NM_001145661.1(GATA2): c.1061C> T (p.Thr354Met)single nucleotide variantPathogenic, risk factorrs387906631GRCh37Chr 3, 128200744: 128200744
2MT-TL1m.3242G> Asingle nucleotide variantPathogenicrs199474668GRCh37Chr MT, 3242: 3242

Expression for genes affiliated with Myelodysplastic Syndromes

About this section
Sources:
2BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Myelodysplastic Syndromes

Search GEO for disease gene expression data for Myelodysplastic Syndromes.

Pathways for genes affiliated with Myelodysplastic Syndromes

About this section
Sources:
50PathCards, 60Thomson Reuters, 38NCBI BioSystems Database, 5Cell Signaling Technology, 30KEGG, 55Reactome, 53QIAGEN
See all sources

Pathways related to Myelodysplastic Syndromes according to GeneCards/GeneDecks:

(show all 16)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.2EPO, EPOR
2
Show member pathways
Paxillin-independent events mediated by a4b1 and a4b738
a4b1 and a4b7 Integrin signaling38
10.2EPOR, EPO
310.1CSF3, CSF2
410.1MNDA, GATA2, IL3
510.0CSF2, CDKN2C, IL3
6
Show member pathways
10.0IL3, NRAS, CSF2
7
Show member pathways
Signaling Pathways in Glioblastoma38
10.0NRAS, CDKN2B, CDKN2C
89.9NRAS, CDKN2B, CDKN2C, CSF2
9
Show member pathways
9.8MPL, EPOR, EPO, IL3, NRAS
10
Show member pathways
9.8EPOR, NRAS, CDKN2C, CDKN2B, IL3
119.8CSF3, IL3, EPO, EPOR, NRAS
12
Show member pathways
9.7CSF3, CSF2, NRAS, EPOR, IL3
13
Show member pathways
Type III interferon signaling38
9.6MPL, IL3, EPO, EPOR, CSF3, CSF2
14
Show member pathways
9.5EPOR, EPO, IL3, CSF2, CSF3, NRAS
15
Show member pathways
9.4EPOR, IL3, CSF2, CDKN2B, CDKN2C, NRAS
169.4EPO, EPOR, DNTT, CSF2, CSF3, CD33

Compounds for genes affiliated with Myelodysplastic Syndromes

About this section
Sources:
45Novoseek, 11DrugBank, 51PharmGKB, 29IUPHAR, 61Tocris Bioscience, 24HMDB
See all sources

Compounds related to Myelodysplastic Syndromes according to GeneCards/GeneDecks:

(show top 50)    (show all 94)
idCompoundScoreTop Affiliating Genes
1erex4510.6EPOR, EPO
2bmmp4510.5IL3, CSF2
3antithymoglobulin4510.5EPO, CSF3
4lenograstim4510.5CSF3, IL3
5nesp4510.5EPO, EPOR
6metenolone acetate4510.5EPO, CSF3
7mps-l4510.5EPO, CSF3
8il 114510.5CSF3, IL3, EPO
9anagrelide45 1111.5CSF2, EPO, MPL
10molgramostim4510.4IL3, CSF3, CSF2
11mesna4510.4CSF2, CSF3, IL3
12thiotepa45 51 1112.4CSF3, CSF2, IL3
13mafosfamide4510.4CSF3, IL3, CSF2
14romurtide4510.4CSF2, CSF3
15ara-ctp4510.4CSF2, CSF3, IL3
164-hydroperoxycyclophosphamide4510.4IL3, CSF2, CSF3
17daniplestim4510.4IL3, CSF3
18idarubicin51 45 1112.4IL3, CSF3, CSF2
19lenalidomide45 1111.4IL3, EPOR, CSF3, EPO
20pegfilgrastim45 1111.4CSF2, EPO, IL3, CSF3
21pixy3214510.3CSF3, IL3, EPO, CSF2
22amifostine45 1111.3EPO, IL3, CSF2, CSF3
23filgrastim45 1111.3CSF3, CSF2, IL3, EPO
24gm-csf45 2911.3EPO, CSF3, CSF2, IL3
25cytoxan4510.3CSF3, IL3
26ribavirin45 51 1112.3CSF3, CSF2, EPO, IL3
27melphalan45 51 1112.3EPO, CSF3, CSF2, IL3
28zidovudine45 51 1112.3CSF2, EPO, IL3, CSF3
29ifosfamide45 1111.3CSF3, CSF2, IL3
30carboxymethylcellulose4510.3CSF3, EPO
31mycophenolate mofetil45 51 1112.2CSF3, EPO, IL3
32mitoxantrone45 51 1112.2IL3, CSF2, CSF3
33cytarabine45 51 1112.2EPO, CDKN2B, CSF3, IL3, CSF2
34leucovorin45 51 1112.2CSF3, CSF2, IL3
35agar4510.2MPL, NRAS, IL3, CSF2, EPOR
36carboplatin45 51 1112.2IL3, CSF2, DNTT, EPO, CSF3
37butyrate4510.1GATA2, CSF2, DNTT, IL3, EPO
38methylcellulose4510.1EPOR, GATA2, CSF3, CSF2, IL3, EPO
39endotoxin4510.1CSF3, CSF2, FTMT, MNDA
40gp 1304510.1MPL, CSF3, EPOR, CSF2, IL3, EPO
41hydroxyurea45 51 1112.1DNTT, EPO, IL3, CSF3, GATA2, CSF2
42n-formylmethionyl-leucylphenylalanine4510.0IL3, CSF2, CSF3
43cisplatin45 51 61 1113.0IL3, EPO, CSF3, CSF2, EPOR, DNTT
44methotrexate51 45 1111.9DNTT, EPO, CDKN2B, CSF3
45vegf459.8EPOR, MPL, ANG, CSF2, CSF3, EPO
465fluorouracil459.8MPL, CSF2, IL3, CSF3
47retinoic acid45 2410.8IL3, BOK, CSF3, GATA2, CSF2, CDKN2B
48thymidine45 2410.7CSF3, CSF2, DNTT, IL3, EPO, EPOR
49fludarabine45 51 1111.7CSF2, DNTT, CSF3
50tyrosine459.5CDKN2B, CD33, NRAS, MPL, EPOR, EPO

GO Terms for genes affiliated with Myelodysplastic Syndromes

About this section
Sources:
16Gene Ontology
See all sources

Cellular components related to Myelodysplastic Syndromes according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1extracellular spaceGO:0056159.8CSF3, CSF2, IL3, ANG, EPO

Biological processes related to Myelodysplastic Syndromes according to GeneCards/GeneDecks:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1embryonic placenta developmentGO:00189210.2GATA2, CSF2
2negative regulation of protein serine/threonine kinase activityGO:07190110.2CDKN2B, CDKN2C
3positive regulation of tyrosine phosphorylation of Stat5 proteinGO:04252310.2CSF2, IL3, EPO
4positive regulation of DNA replicationGO:04574010.1EPO, IL3, CSF2
5oligodendrocyte differentiationGO:04870910.0CDKN2C, BOK
6negative regulation of phosphorylationGO:0423269.9CDKN2B, CDKN2C
7positive regulation of cell proliferationGO:0082849.8NRAS, EPO, FTMT, IL3, CSF2, CSF3

Molecular functions related to Myelodysplastic Syndromes according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein serine/threonine kinase inhibitor activityGO:00486110.2CDKN2B, CDKN2C
2cytokine activityGO:00512510.0CSF3, IL3, CSF2
3growth factor activityGO:0080839.7CSF2, CSF3, IL3
4protein bindingGO:0055158.8MNDA, EPOR, EPO, ASXL1, ANG, CSF2

Products for genes affiliated with Myelodysplastic Syndromes

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Myelodysplastic Syndromes

About this section
4CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
52PubMed
53QIAGEN
59SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet